ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
24. Oktober 2023 04:00 ET | AKAMPION
Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress...
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
17. Oktober 2023 04:00 ET | AKAMPION
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors   ...
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
24. Mai 2023 04:00 ET | AKAMPION
- First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...
HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer
23. November 2022 04:00 ET | AKAMPION
- Significant expansion of allergy research expertise Geneva, Switzerland, November 23, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against...
Therapeutics Solutions International, Inc LOGO.png
Therapeutic Solutions International Inc. Reports Revenues Up 850% for Q2
29. August 2019 13:53 ET | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - Therapeutics Solutions International Inc. (OTC: TSOI) today reports that its second-quarter 2019 revenues increased 850%, as...
Therapeutics Solutions International, Inc LOGO.png
Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients
26. August 2019 09:00 ET | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today positive results from a pilot clinical trial...
Therapeutics Solutions International, Inc LOGO.png
Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development
05. August 2019 09:00 ET | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) together with The Right to Try Foundation announced filing of a...
Therapeutics Solutions International, Inc LOGO.png
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer
29. Juli 2019 09:00 ET | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) reported today positive animal data demonstrating synergy at...
Therapeutics Solutions International, Inc LOGO.png
Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of NanoPSA
11. Juli 2019 09:00 ET | Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the further development of a mustard seed...